IPOGrid
0001880995
IPO filing research
Alopexx, Inc.
Biological Products, (No Diagnostic Substances) · ALPX
ipo
amended
NYSE American
S-1/A
Alopexx, Inc. IPO research page with SEC filing history, offering status, deal terms, structured filing extracts, company news, and comparable IPO context. Latest filing: S-1/A on 2026-06-26. Current deal snapshot: exchange NYSE American.
Filing Timeline
SEC EDGAR
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Price $11.00 · Range $10.00 to $12.00 · 3,000,000 shares · Gross proceeds $33,000,000
Common Stock · Exchange NYSE American · Ticker ALPX · Over-allotment 450,000 · Use of proceeds General corporate purposes · Underwriters ThinkEquity
2026-06-26 · 0001213900-26-072480
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Price $5.00 · 2,700,000 shares · Gross proceeds $12,000,000
Common Stock · Exchange NYSE American · Ticker ALPX · Over-allotment 360,000 · Use of proceeds Working capital, operations, and general corporate purposes · Underwriters ThinkEquity
2025-02-25 · 0001213900-25-016709
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Price $5.00 · 2,400,000 shares · Gross proceeds $12,000,000
Common Stock · Exchange NYSE American · Ticker ALPX · Over-allotment 360,000 · Use of proceeds Proceeds from the primary offering will be used for general corporate purposes, and selling stockholders will receive proceeds from the resale of their shares. · Underwriters ThinkEquity
2025-01-08 · 0001839882-25-001330
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Price $5.00 · 2,400,000 shares · Gross proceeds $12,000,000
Common Stock · Exchange NYSE American · Ticker ALPX · Over-allotment 360,000 · Use of proceeds working capital, research and development, and other general corporate purposes · Underwriters ThinkEquity
2024-09-09 · 0001999371-24-011702
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Price $5.00 · 3,000,000 shares · Gross proceeds $15,000,000
Common Stock · Exchange NYSE American · Ticker ALPX · Over-allotment 450,000 · Flags emerging_growth_company · Underwriters ThinkEquity
2024-03-14 · 0001999371-24-003528
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior FWP filing.
Price $5.00 · 3,000,000 shares · Gross proceeds $15,000,000
Common Stock · Exchange NYSE American · Ticker ALPX · Over-allotment 450,000 · Use of proceeds for general corporate purposes · Underwriters ThinkEquity
2023-12-27 · 0001999371-23-001220
FWP
supplemental
Free writing prospectus
Prospectus supplement or marketing filing that often updates active offering terms.
Follows S-1/A and supplements the active offering with updated prospectus details.
Price $5.00 · 3,000,000 shares · Gross proceeds $15,000,000
Common Stock · Exchange Nasdaq · Ticker ALPX · Over-allotment 450,000 · Use of proceeds Advance clinical trials, manufacturing, general corporate purposes · Underwriters ThinkEquity
2023-02-01 · 0001387131-23-001142
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Price $5.00 · 3,000,000 shares · Gross proceeds $15,000,000
Common Stock · Exchange Nasdaq · Ticker ALPX · Over-allotment 450,000 · Use of proceeds For working capital and other general corporate purposes · Flags emerging_growth_company · Underwriters ThinkEquity
2023-02-01 · 0001387131-23-001140
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Price $5.00 · 3,000,000 shares · Gross proceeds $15,000,000
Common · Exchange Nasdaq Capital Market · Ticker ALPX · Over-allotment 450,000 · Use of proceeds for general corporate purposes · Underwriters ThinkEquity
2022-12-15 · 0001387131-22-012441
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Price $5.00 · 3,000,000 shares · Gross proceeds $15,000,000
Common Stock · Exchange Nasdaq · Ticker ALPX · Over-allotment 450,000 · Use of proceeds to fund operations and for general corporate purposes · Underwriters ThinkEquity
2022-11-18 · 0001387131-22-011531
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior 8-A12B filing.
2022-10-07 · 0001387131-22-010319
8-A12B
effective
Exchange Act registration
Registration filed to list the securities under the Exchange Act ahead of trading.
Follows FWP and registers the class of securities for exchange listing.
2022-10-06 · 0001839882-22-023019
FWP
supplemental
Free writing prospectus
Prospectus supplement or marketing filing that often updates active offering terms.
Follows S-1/A and supplements the active offering with updated prospectus details.
Alopexx, Inc. is advancing two pipeline candidates, mAb F598 and vaccine AV0328, targeting PNAG (Poly N-Acetyl Glucosamine) for broad-spectrum infectious disease prevention. AV0328, a single-component vaccine, aims to complement existing serotype-specific vaccines for S. pneumoniae and N. meningitidis, with potential market revenues exceeding $3B. mAb F598 focuses on preventing ICU hospital-acquired infections (HAIs) caused by antibiotic-resistant pathogens. Both candidates have completed early-phase trials, with AV0328 in Phase II and mAb F598 progressing toward larger studies. The company emphasizes its IP portfolio and partnerships, including collaborations with Paris APHP and key opinion leaders like Dr. David Skurnik.
2022-09-07 · 0001387131-22-009525
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior FWP filing.
Price $5.00 · 3,000,000 shares · Gross proceeds $15,000,000
Common Stock · Exchange Nasdaq · Ticker ALPX · Over-allotment 450,000 · Use of proceeds Gross proceeds are expected to be at least $15,000,000 · Underwriters ThinkEquity
2022-09-07 · 0001387131-22-009513
FWP
supplemental
Free writing prospectus
Prospectus supplement or marketing filing that often updates active offering terms.
Follows S-1/A and supplements the active offering with updated prospectus details.
Range $5.00 to $7.00 · 2,500,000 shares · Gross proceeds $15,000,000
Common Stock · Exchange Nasdaq · Ticker ALPX · Over-allotment 375,000 · Use of proceeds Advance clinical trials, manufacturing, and general corporate purposes · Underwriters ThinkEquity
Alopexx, Inc. is developing immune therapeutics targeting PNAG (Poly N-Acetyl Glucosamine), a surface component of various bacteria and fungi, to address antibiotic-resistant infections and broaden vaccine coverage. The company's pipeline includes mAb F598 for preventing ICU hospital-acquired infections and Vaccine AV0328, a potential broad-spectrum pneumococcal and meningitis vaccine. Both candidates are in Phase II readiness, with market potential exceeding $4 billion. The filing highlights strong IP protection, a seasoned management team, and partnerships for clinical trials, positioning Alopexx to reduce antibiotic reliance and address unmet medical needs in infectious diseases.
2022-08-25 · 0001839882-22-018437
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Range $5.00 to $7.00 · 2,500,000 shares
Common Stock · Exchange Nasdaq Capital Market · Ticker ALPX · Over-allotment 375,000 · Use of proceeds for general corporate purposes · Underwriters ThinkEquity
2022-08-24 · 0001387131-22-009029
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Common Stock · Exchange Nasdaq Capital Market · Ticker ALPX · Use of proceeds working capital · Underwriters ThinkEquity
2022-07-12 · 0001387131-22-007654
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Common Stock · Exchange Nasdaq Capital Market · Ticker ALPX · Underwriters ThinkEquity
2022-05-31 · 0001387131-22-006625
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Common Stock of Alopexx, Inc. · Exchange Nasdaq Capital Market · Ticker ALPX · Underwriters ThinkEquity
2022-05-02 · 0001387131-22-005622
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Common Stock · Exchange Nasdaq Capital Market · Ticker ALPX · Use of proceeds Proceeds will be used for general corporate purposes · Underwriters ThinkEquity
2022-04-20 · 0001387131-22-005035
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1 filing.
Exchange Nasdaq · Ticker ALPX · Underwriters ThinkEquity
Alopexx, Inc. details significant risks related to third-party manufacturing dependencies, clinical trial delays, regulatory approvals, and product safety in its S-1/A filing. The company emphasizes continued reliance on contract manufacturers like Lonza and Glycosyn, highlighting vulnerabilities in supply chain stability, compliance with cGMPs, and potential disruptions from natural disasters or pandemics. Clinical development faces challenges including patient enrollment difficulties, adverse trial outcomes, and regulatory hurdles. The filing also underscores risks of product liability, public perception issues, and the impact of manufacturing process changes on development timelines and commercialization.
2022-04-07 · 0001387131-22-004650
S-1
filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows DRS in the pre-IPO sequence.
Common Stock of Alopexx, Inc. · Exchange Nasdaq Capital Market · Ticker ALOP · Use of proceeds General corporate purposes · Underwriters ThinkEquity
Alopexx, Inc. is seeking regulatory approvals for its vaccine and antibody, emphasizing reliance on third-party manufacturers like Lonza and Glycosyn. The company highlights dependencies on CDC and ACIP recommendations for market success, noting risks from manufacturing challenges, regulatory hurdles, and potential adverse effects. Clinical trials face delays due to pandemic disruptions, supply chain issues, and compliance requirements. Market acceptance hinges on physician and patient trust, with significant risks tied to clinical trial outcomes and competitive pressures.
2022-03-07 · 0001387131-22-003216
DRS
filed
Draft registration statement
Draft registration filed confidentially before the public launch.
First tracked pre-IPO filing for this issuer.
2022-01-07 · 0001387131-22-000166
Comparable Deals
17 comparable deals
Healthcare & BiotechMicro (<$50M)Last 18 months
Only 0 strict matches; expanded to 17 using nearest neighbors.
Showing top 8 by similarity.
Aardvark Therapeutics, Inc.
AARD
same SIC grouprecent IPO
Odyssey Therapeutics, Inc.
ODTX
same SICrecent IPO
Agomab Therapeutics NV
AGMB
same SICrecent IPO
Radiopharm Theranostics Ltd
RADX
same SIC groupnearby deal sizeolder IPO
SL Science Holding Ltd
SLBT
same SICrecent IPO
Hemab Therapeutics Holdings, Inc.
COAG
same SICrecent IPO
Kardigan, Inc.
KARD
same SIC grouprecent IPO
Seaport Therapeutics, Inc.
SPTX
same SIC grouprecent IPO
Recent News
No recent news stored for this issuer.